cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.24865115
title: High risks adverse events associated with usage of aspirin in chronic obstructive pulmonary disease

description: Despite potential benefits and widespread prescription of aspirin among chronic obstructive pulmonary disease (COPD) patients, limited research has investigated its adverse effects (AEs) in COPD population. We conducted a retrospective analysis of adverse drug events (ADEs) reported in the US Food and Drug Administration Adverse Event Reporting System (FAERS) between Q1 2013 and Q2 2022. COPD patients were categorized into two groups based on aspirin use. ADEs related to aspirin use were identified using combined reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC) methods. A total of 56,660 ADEs reports associated with COPD patients were included in the study. Among these reports, 144 adverse events were linked to aspirin use in COPD patients, including fatigue (4.12%), diarrhea (3.13%), dyspnea exertional (2.03%), rhinorrhea (1.99%), weight increased (1.89%) and vomiting (1.84%), muscle spasms (1.79%), cardiac disorder (1.74%), heart rate increased (1.69%) and peripheral swelling (1.59%). Subgroup analysis indicates that age and gender might affect the AEs frequency in COPD patients using aspirin. Our findings identify 10 most frequently reported ADEs associated with aspirin use in COPD patients, thus offer valuable insights into the AEs of aspirin for safer clinical utilization in COPD management.
DOI: 10.6084/m9.figshare.24865115.v1
title: High risks adverse events associated with usage of aspirin in chronic obstructive pulmonary disease

description: Despite potential benefits and widespread prescription of aspirin among chronic obstructive pulmonary disease (COPD) patients, limited research has investigated its adverse effects (AEs) in COPD population. We conducted a retrospective analysis of adverse drug events (ADEs) reported in the US Food and Drug Administration Adverse Event Reporting System (FAERS) between Q1 2013 and Q2 2022. COPD patients were categorized into two groups based on aspirin use. ADEs related to aspirin use were identified using combined reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC) methods. A total of 56,660 ADEs reports associated with COPD patients were included in the study. Among these reports, 144 adverse events were linked to aspirin use in COPD patients, including fatigue (4.12%), diarrhea (3.13%), dyspnea exertional (2.03%), rhinorrhea (1.99%), weight increased (1.89%) and vomiting (1.84%), muscle spasms (1.79%), cardiac disorder (1.74%), heart rate increased (1.69%) and peripheral swelling (1.59%). Subgroup analysis indicates that age and gender might affect the AEs frequency in COPD patients using aspirin. Our findings identify 10 most frequently reported ADEs associated with aspirin use in COPD patients, thus offer valuable insights into the AEs of aspirin for safer clinical utilization in COPD management.
DOI: 10.6084/m9.figshare.25234834
title: Bayesian or frequentist: there is no question when comparing single-inhaler triple therapies via network meta-analysis. Focus on fluticasone furoate/umeclidinium/vilanterol fixed-dose combination in chronic obstructive pulmonary disease

description: Single-inhaler triple therapies (SITTs) have never been directly compared in randomized controlled trials (RCTs) in chronic obstructive pulmonary disease (COPD). Cochrane recommends the Bayesian approach for indirect comparisons but a frequentist network meta-analysis (NMA) reported superiority of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) over other SITT. We assessed the most appropriate inference method for NMA characterized by between-study heterogeneity on SITT in COPD. Bayesian and frequentist NMA were performed on RCTs investigating the effect of SITT on exacerbations and trough forced expiratory volume in the 1<sup>st</sup> second (FEV<sub>1</sub>) in COPD. The included RCTs (ETHOS, FULFIL, IMPACT, KRONOS 200812) reported significant between-study heterogeneity (I<sup>2</sup> &gt; 99%, <i>p</i> &lt; 0.001). The Bayesian random-effect NMA provided unbiased evidence that FF/UMEC/VI was not superior to other SITT on exacerbations and trough FEV<sub>1</sub>. The frequentist fixed-effect NMA indicated that FF/UMEC/VI was significantly (<i>p</i> &lt; 0.05) more effective than other SITT, although results were affected by dispersion, asymmetry, and significant risk of bias. Frequentist random-effect NMA provided effect estimates rather similar but not equal to those of Bayesian approach. Indirect comparison should be performed via Bayesian approach instead of frequentist inference with a fixed-effect model. Claiming the superiority of a specific medication over other therapies should be confirmed by findings originating from well-designed RCTs.
DOI: 10.6084/m9.figshare.25234834.v1
title: Bayesian or frequentist: there is no question when comparing single-inhaler triple therapies via network meta-analysis. Focus on fluticasone furoate/umeclidinium/vilanterol fixed-dose combination in chronic obstructive pulmonary disease

description: Single-inhaler triple therapies (SITTs) have never been directly compared in randomized controlled trials (RCTs) in chronic obstructive pulmonary disease (COPD). Cochrane recommends the Bayesian approach for indirect comparisons but a frequentist network meta-analysis (NMA) reported superiority of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) over other SITT. We assessed the most appropriate inference method for NMA characterized by between-study heterogeneity on SITT in COPD. Bayesian and frequentist NMA were performed on RCTs investigating the effect of SITT on exacerbations and trough forced expiratory volume in the 1<sup>st</sup> second (FEV<sub>1</sub>) in COPD. The included RCTs (ETHOS, FULFIL, IMPACT, KRONOS 200812) reported significant between-study heterogeneity (I<sup>2</sup> &gt; 99%, <i>p</i> &lt; 0.001). The Bayesian random-effect NMA provided unbiased evidence that FF/UMEC/VI was not superior to other SITT on exacerbations and trough FEV<sub>1</sub>. The frequentist fixed-effect NMA indicated that FF/UMEC/VI was significantly (<i>p</i> &lt; 0.05) more effective than other SITT, although results were affected by dispersion, asymmetry, and significant risk of bias. Frequentist random-effect NMA provided effect estimates rather similar but not equal to those of Bayesian approach. Indirect comparison should be performed via Bayesian approach instead of frequentist inference with a fixed-effect model. Claiming the superiority of a specific medication over other therapies should be confirmed by findings originating from well-designed RCTs.
DOI: 10.6084/m9.figshare.25248136.v1
title: Data_Paper.zip

description: Recovering whole-body angular momentum and margin of stability after treadmill-induced perturbations during sloped walking in healthy young adults
DOI: 10.57770/lbojum
title: Temporal alpha dissimilarity of ADHD brain network in comparison with CPT and CATA

description: This supplementary material comprises the anonymized raw data and grouped data of all 72 participants involved in the study. The dataset is essential for researchers seeking detailed insights into the effects of electroencephalography (EEG), attention deficit/hyperactivity disorder (ADHD), and brain-computer interface (BCI). It serves as a valuable resource for further research and advanced statistical analysis. Participant Raw Data: Contains individual records for each of the 36 participants. The data is anonymized to ensure privacy and ethical compliance. Grouped Data: The participants were categorized into two distinct groups, employing a counterbalanced design. This organization facilitates easier comparative analysis and interpretation of the data. (2024-02-06)
DOI: 10.6084/m9.figshare.8222735
title: Additional file 5: of The adaptation strategies of Herpetospermum pedunculosum (Ser.) Baill at altitude gradient of the Tibetan plateau by physiological and metabolomic methods

description: Table S3. on metabolites identified in Herpetospermum caudigerum Wall., showing their molecular masses, KEGG compound codes, suggested metabolic functions, and the corresponding KEGG pathway codes. (XLS 31 kb)
DOI: 10.6084/m9.figshare.8222735.v1
title: Additional file 5: of The adaptation strategies of Herpetospermum pedunculosum (Ser.) Baill at altitude gradient of the Tibetan plateau by physiological and metabolomic methods

description: Table S3. on metabolites identified in Herpetospermum caudigerum Wall., showing their molecular masses, KEGG compound codes, suggested metabolic functions, and the corresponding KEGG pathway codes. (XLS 31 kb)
DOI: 10.6084/m9.figshare.8222753
title: Additional file 8: of The adaptation strategies of Herpetospermum pedunculosum (Ser.) Baill at altitude gradient of the Tibetan plateau by physiological and metabolomic methods

description: Table S4–1. All of the metabolites identified in leaves of Herpetospermum pedunculosum (Ser.) Baill. Table S4–2. The difference of metabolites in Herpetospermum pedunculosum (Ser.) Baill leaves between 3000 m and 2800 m altitude. Table S4–3. The difference of metabolites in Herpetospermum pedunculosum (Ser.) Baill leaves between 3100 m and 2800 m altitude. Table S4–3. The difference of metabolites in Herpetospermum pedunculosum (Ser.) Baill leaves between 3300 m and 2800 m altitude. (XLSX 336 kb)
DOI: 10.6084/m9.figshare.8222753.v1
title: Additional file 8: of The adaptation strategies of Herpetospermum pedunculosum (Ser.) Baill at altitude gradient of the Tibetan plateau by physiological and metabolomic methods

description: Table S4–1. All of the metabolites identified in leaves of Herpetospermum pedunculosum (Ser.) Baill. Table S4–2. The difference of metabolites in Herpetospermum pedunculosum (Ser.) Baill leaves between 3000 m and 2800 m altitude. Table S4–3. The difference of metabolites in Herpetospermum pedunculosum (Ser.) Baill leaves between 3100 m and 2800 m altitude. Table S4–3. The difference of metabolites in Herpetospermum pedunculosum (Ser.) Baill leaves between 3300 m and 2800 m altitude. (XLSX 336 kb)
DOI: 10.6084/m9.figshare.7698536
title: MOESM2 of Inside 50,000 living rooms: an assessment of global residential ornamentation using transfer learning

description: Multi-page .csv of all 107 cities and element counts. Table of all global cities with average rates of decor prevalence for each indicator. (CSV 7 kB)
DOI: 10.6084/m9.figshare.7698536.v1
title: MOESM2 of Inside 50,000 living rooms: an assessment of global residential ornamentation using transfer learning

description: Multi-page .csv of all 107 cities and element counts. Table of all global cities with average rates of decor prevalence for each indicator. (CSV 7 kB)
DOI: 10.6084/m9.figshare.9795749
title: Effect of iguratimod on diclofenac metabolism by CYP2C9 in rats and human recombinant CYP2C9 yeast cells

description: Iguratimod (IGU, also known as T-614), a novel disease modifying antirheumatic drug intended to cure patients with rheumatoid arthritis (RA). The purpose of this study is to evaluate the effect of IGU on the pharmacokinetics of CYP2C9 probe drug diclofenac and its metabolite 4′-hydroxy diclofenac in vivo and in vitro. In in vivo experiments, 24 rats were randomly assigned to three groups consisting of the control group (Normal saline), low dose IGU group (10 mg/kg) and high dose IGU group (30 mg/kg). Blood samples were collected from orbital sinuses vein before 1 hour and serial times of giving diclofenac (15 mg/kg) to all the rats. Plasma concentration of diclofenac and its metabolite 4´-hydroxy diclofenac were assayed by high performance liquid chromatography. Pharmacokinetic parameters were assessed by Winnonlin 6.4 pharmacokinetic software. Moreover, in vitro studies were performed in recombinant human CYP2C9 yeast cell system. IGU at low dose showed no significant differences in the pharmacokinetic parameters of diclofenac and 4-hydroxy diclofenac in vivo when compared with control group (p&gt;0.005). However, at the high dose of IGU, the pharmacokinetic parameters of 4´-hydroxy metabolite of diclofenac increase in half-life (T1/2) and mean area under the curve (AUC0→24), while a decrease in mean clearance (CL, mL/h/kg) and volume of distribution Vz (mL/kg). In addition, in in vitro study, high doses of IGU reduces the metabolism rate of diclofenac. IGU at high dose significantly increase the pharmacokinetics parameters of 4´-hydroxy diclofenac in rats. Additionally, it also showed the potent inhibitory effect on diclofenac metabolism in recombinant human CYP2C9 yeast cells.
DOI: 10.6084/m9.figshare.9795749.v1
title: Effect of iguratimod on diclofenac metabolism by CYP2C9 in rats and human recombinant CYP2C9 yeast cells

description: Iguratimod (IGU, also known as T-614), a novel disease modifying antirheumatic drug intended to cure patients with rheumatoid arthritis (RA). The purpose of this study is to evaluate the effect of IGU on the pharmacokinetics of CYP2C9 probe drug diclofenac and its metabolite 4′-hydroxy diclofenac in vivo and in vitro. In in vivo experiments, 24 rats were randomly assigned to three groups consisting of the control group (Normal saline), low dose IGU group (10 mg/kg) and high dose IGU group (30 mg/kg). Blood samples were collected from orbital sinuses vein before 1 hour and serial times of giving diclofenac (15 mg/kg) to all the rats. Plasma concentration of diclofenac and its metabolite 4´-hydroxy diclofenac were assayed by high performance liquid chromatography. Pharmacokinetic parameters were assessed by Winnonlin 6.4 pharmacokinetic software. Moreover, in vitro studies were performed in recombinant human CYP2C9 yeast cell system. IGU at low dose showed no significant differences in the pharmacokinetic parameters of diclofenac and 4-hydroxy diclofenac in vivo when compared with control group (p&gt;0.005). However, at the high dose of IGU, the pharmacokinetic parameters of 4´-hydroxy metabolite of diclofenac increase in half-life (T1/2) and mean area under the curve (AUC0→24), while a decrease in mean clearance (CL, mL/h/kg) and volume of distribution Vz (mL/kg). In addition, in in vitro study, high doses of IGU reduces the metabolism rate of diclofenac. IGU at high dose significantly increase the pharmacokinetics parameters of 4´-hydroxy diclofenac in rats. Additionally, it also showed the potent inhibitory effect on diclofenac metabolism in recombinant human CYP2C9 yeast cells.
DOI: 10.6084/m9.figshare.11368689
title: Impact of KRAS mutation status on outcomes of metastatic colorectal cancer treated with anti-angiogenic agents: a meta-analysis

description: The impact of KRAS mutation status on outcomes of metastatic colorectal cancer (mCRC) treated with anti-angiogenic agents is controversial. A total of 4,066 mCRC patients from nine randomized controlled trials (RCTs) were included for analysis. The pooled results showed that the use of anti-angiogenic agents significantly improved progression-free survival (PFS) in mCRC patients with KRAS wide type (HR 0.63, 95%CI: 0.53–0.75, p&lt;0.001) or mutated (HR 0.55, 95%CI: 0.38–0.79, p=0.001). In addition, the use of anti-angiogenic agents significantly improved overall survival (OS) in mCRC patients with KRAS wide type (HR 0.78, 95%CI: 0.70–0.86, p&lt;0.001) or KRAS mutant status (HR 0.87, 95%CI: 0.77–0.98, p=0.018). No publication bias was detected for OS and PFS in mCRC patients. The findings of this study show that the use of anti-angiogenic agents significantly improved PFS and OS in mCRC independent of K-RAS gene status. KRAS gene status does not significantly influence the activity of antiangiogenic agents.
DOI: 10.6084/m9.figshare.11368689.v1
title: Impact of KRAS mutation status on outcomes of metastatic colorectal cancer treated with anti-angiogenic agents: a meta-analysis

description: The impact of KRAS mutation status on outcomes of metastatic colorectal cancer (mCRC) treated with anti-angiogenic agents is controversial. A total of 4,066 mCRC patients from nine randomized controlled trials (RCTs) were included for analysis. The pooled results showed that the use of anti-angiogenic agents significantly improved progression-free survival (PFS) in mCRC patients with KRAS wide type (HR 0.63, 95%CI: 0.53–0.75, p&lt;0.001) or mutated (HR 0.55, 95%CI: 0.38–0.79, p=0.001). In addition, the use of anti-angiogenic agents significantly improved overall survival (OS) in mCRC patients with KRAS wide type (HR 0.78, 95%CI: 0.70–0.86, p&lt;0.001) or KRAS mutant status (HR 0.87, 95%CI: 0.77–0.98, p=0.018). No publication bias was detected for OS and PFS in mCRC patients. The findings of this study show that the use of anti-angiogenic agents significantly improved PFS and OS in mCRC independent of K-RAS gene status. KRAS gene status does not significantly influence the activity of antiangiogenic agents.
DOI: 10.6084/m9.figshare.8222966
title: Additional file 1: of Genetic characteristics and virulence of Listeria monocytogenes isolated from fresh vegetables in China

description: Table S1. The detail detection results of Listeria monocytogenes in 419 vegetable samples. Table S2. Listeria monocytogenes strains isolated from fresh vegetables Figure S1. Serogroup analysis of Listeria monocytogenes strains isolated from fresh vegetable samples by multiplex PCR. The strain no. 1â 30 correspond to Table S2. Figure S2. The presence of virulence-related genes in Listeria monocytogenes isolated from fresh vegetable samples. A, prfA; B, mpl; C, plcA; D, inlB; E, plcA; F, hly; G, iap; H, actA; I, llsX; J, ptsA.*:The strain no. 1â 30 correspond to Additional file 1: Table S2. (ZIP 8979 kb)
DOI: 10.6084/m9.figshare.8222966.v1
title: Additional file 1: of Genetic characteristics and virulence of Listeria monocytogenes isolated from fresh vegetables in China

description: Table S1. The detail detection results of Listeria monocytogenes in 419 vegetable samples. Table S2. Listeria monocytogenes strains isolated from fresh vegetables Figure S1. Serogroup analysis of Listeria monocytogenes strains isolated from fresh vegetable samples by multiplex PCR. The strain no. 1â 30 correspond to Table S2. Figure S2. The presence of virulence-related genes in Listeria monocytogenes isolated from fresh vegetable samples. A, prfA; B, mpl; C, plcA; D, inlB; E, plcA; F, hly; G, iap; H, actA; I, llsX; J, ptsA.*:The strain no. 1â 30 correspond to Additional file 1: Table S2. (ZIP 8979 kb)
DOI: 10.6084/m9.figshare.8222993
title: Additional file 3: of Application of high-throughput amplicon sequencing-based SSR genotyping in genetic background screening

description: Table S2 Primers for the detection of 396 SSR loci. (XLSX 35 kb)
DOI: 10.6084/m9.figshare.8222993.v1
title: Additional file 3: of Application of high-throughput amplicon sequencing-based SSR genotyping in genetic background screening

description: Table S2 Primers for the detection of 396 SSR loci. (XLSX 35 kb)
DOI: 10.6084/m9.figshare.8222987
title: Additional file 2: of Application of high-throughput amplicon sequencing-based SSR genotyping in genetic background screening

description: Table S1 Primers for vector construction, Xa21 detection and gene expression analysis. (XLSX 12 kb)
DOI: 10.6084/m9.figshare.8222987.v1
title: Additional file 2: of Application of high-throughput amplicon sequencing-based SSR genotyping in genetic background screening

description: Table S1 Primers for vector construction, Xa21 detection and gene expression analysis. (XLSX 12 kb)
DOI: 10.6084/m9.figshare.8222999
title: Additional file 4: of Application of high-throughput amplicon sequencing-based SSR genotyping in genetic background screening

description: Table S3 Total SSRs detected in D62B, DXB, DXT and Xa21m. The genotype is the major genotype of the SSR locus, represented as the repeat unit with the repeat number, e.g., CGC4. The coverage represents the number of reads that supported the genotype. The stutter ratio represents the ratio of read numbers of the minor and major genotypes. The name in the national standard represents the name of the differential SSR in the National Agricultural Standard of China No. NY/T 1433â 3014. (XLSX 45 kb)
DOI: 10.6084/m9.figshare.8222999.v1
title: Additional file 4: of Application of high-throughput amplicon sequencing-based SSR genotyping in genetic background screening

description: Table S3 Total SSRs detected in D62B, DXB, DXT and Xa21m. The genotype is the major genotype of the SSR locus, represented as the repeat unit with the repeat number, e.g., CGC4. The coverage represents the number of reads that supported the genotype. The stutter ratio represents the ratio of read numbers of the minor and major genotypes. The name in the national standard represents the name of the differential SSR in the National Agricultural Standard of China No. NY/T 1433â 3014. (XLSX 45 kb)
DOI: 10.6084/m9.figshare.17135906
title: Athlete Sub304

description: EEG and ET mat format data of one Archery Athlete Sub304 in ABT and CCT experiments.
DOI: 10.6084/m9.figshare.17135906.v1
title: Athlete Sub304

description: EEG and ET mat format data of one Archery Athlete Sub304 in ABT and CCT experiments.
DOI: 10.6084/m9.figshare.8223011
title: Additional file 5: of Application of high-throughput amplicon sequencing-based SSR genotyping in genetic background screening

description: Table S4 Valid and comparable SSRs in DXB and D62B. The valid SSR loci in each sample are those SSR loci covered by at least 10 reads and with stutter ratios lower than 0.5. Comparable SSRs between two samples are those SSR loci that are valid in both samples. The genotype is the major genotype of the SSR locus, represented as the repeat unit with the repeat number, e.g., CGC4. The coverage represents the number of reads that support the genotype. The stutter ratio represents the ratio of the read numbers of the minor and major genotypes. Asterisks represent the differential SSRs between two samples; &gt; 5, 0 and 1–5 represent the length differences of differential SSRs between two samples. SSRs with length differences less than 5 bp were hardly distinguished by electrophoresis. The name in the national standard represents the name of the differential SSR in the National Agricultural Standard of China No. NY/T 1433–3014. The MSU ID shows the gene symbols of the genes in which the different SSRs are distributed. The region of genes represents the region of the differential SSR within the gene, e.g., the UTR. (XLSX 40 kb)
DOI: 10.6084/m9.figshare.8223011.v1
title: Additional file 5: of Application of high-throughput amplicon sequencing-based SSR genotyping in genetic background screening

description: Table S4 Valid and comparable SSRs in DXB and D62B. The valid SSR loci in each sample are those SSR loci covered by at least 10 reads and with stutter ratios lower than 0.5. Comparable SSRs between two samples are those SSR loci that are valid in both samples. The genotype is the major genotype of the SSR locus, represented as the repeat unit with the repeat number, e.g., CGC4. The coverage represents the number of reads that support the genotype. The stutter ratio represents the ratio of the read numbers of the minor and major genotypes. Asterisks represent the differential SSRs between two samples; &gt; 5, 0 and 1–5 represent the length differences of differential SSRs between two samples. SSRs with length differences less than 5 bp were hardly distinguished by electrophoresis. The name in the national standard represents the name of the differential SSR in the National Agricultural Standard of China No. NY/T 1433–3014. The MSU ID shows the gene symbols of the genes in which the different SSRs are distributed. The region of genes represents the region of the differential SSR within the gene, e.g., the UTR. (XLSX 40 kb)